Shares in Allergy Therapeutics rose more than 20 per cent after it said it planned to file with European regulators early next year for an allergy vaccine following positive results from a late-stage clinical trial.

Patients suffering seasonal allergic rhino-conjunctivitis caused by hayfever from grass pollen who received its Pollinex Quattro vaccine reported a 13 per cent improvement over those taking a placebo.